A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza

Antiviral Therapy

Volumn 23, Issue 2, 2018, Pages 157-165

  Higashiguchi, Masayoshi ^a   Matsumoto, Tomoshige ^a   Fujii, Takashi ^a  

^a Department of Medicine Osaka Anti Tuberculosis Association Osaka Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; PLACEBO; ZANAMIVIR; ANTIVIRUS AGENT; LANINAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DISEASE DURATION; FEVER; HUMAN; INCIDENCE; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); META ANALYSIS; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; VIRUS MUTATION; COMBINATION DRUG THERAPY; DISEASE MANAGEMENT; DRUG EFFECT; INFLUENZA; INFLUENZA A VIRUS; INFLUENZAVIRUS B; INHALATIONAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VIROLOGY;

ADMINISTRATION, INHALATION; ANTIVIRAL AGENTS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INFLUENZAVIRUS B; POST-EXPOSURE PROPHYLAXIS; TREATMENT OUTCOME; ZANAMIVIR;

EID: 85047127606     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3189     Document Type: Article

References (32)

1. Paules C, Subbarao K. Influenza. Lancet 2017; 390:697–708.
2. Rajagopal S, Treanor J. Pandemic (avian) influenza. Semin Respir Crit Care Med 2007; 28:159–170.
3. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. N Engl J Med 2010; 362:1708–1719.
4. Treanor JJ. Influenza vaccination. N Engl J Med 2016; 375:1261–1268.
5. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363–1373.
6. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4:CD008965.
7. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729–1737.
8. Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One 2014; 9:e113633.
9. Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother 2010; 21:71–84.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
11. PEDro scale. (Accessed 10 January 2018.) Available from https://www.pedro.org.au/wp-content/uploads/PEDro_scale.pdf
12. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (Accessed 10 January 2018.) Available from http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf
13. Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med 1987; 6:11–29.
14. Michiels S, Piedbois P, Burdett S, et al. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 2005; 21:119–125.
15. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105:429–435.
16. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2017. (Accessed 10 January 2018.) Available from https://www.R-project.org/
17. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36:1–48.
18. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575–2582.
19. Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167–1175.
20. Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. J Infect Chemother 2012; 18:858–864.
21. Watanabe A. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother 2013; 19:89–97.
22. Kawai N, Ikematsu H, Kawashima T, et al. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B. Influenza Other Respir Viruses 2013; 7:448–455.
23. Takemoto Y, Asai T, Ikezoe I, et al. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. Chemotherapy 2013; 59:373–378.
24. Koseki N, Kaiho M, Kikuta H, et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza Other Respir Viruses 2014; 8:151–158.
25. Sugaya N, Sakai-Tagawa Y, Bamba M, et al. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Antivir Ther 2015; 20:49–55.
26. Yoshino Y, Seo K, Koga I, Kitazawa T, Ota Y. Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial. Infect Dis (Lond) 2017; 49:417–419.
27. Kashiwagi S, Watanabe A, Ikematsu H, et al. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother 2013; 19:740–749.
28. Kashiwagi S, Watanabe A, Ikematsu H, Uemori M, Awamura S, Laninamivir Prophylaxis Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza. Clin Infect Dis 2016; 63:330–337.
29. Nakano T, Ishiwada N, Sumitani T, Uemori M, Isobe K, Laninamivir Prophylaxis Study Group. Inhaled laninamivir octanoate as prophylaxis for influenza in children. Pediatrics 2016; 138:e20160109.
30. Hikita T, Hikita H, Hikita F, Hikita N, Hikita S. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr 2012; 2012:834181.
31. Nakano T, Shiosakai K. Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor. J Infect Chemother 2014; 20:401–406.
32. Velkov T, Abdul Rahim N, Zhou QT, Chan HK, Li J. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv Drug Deliv Rev 2015; 85:65–82.